From a Fledgling Genetic Science, A Murky Market for Predictions
By Ashley Smart,
Undark
| 10. 27. 2023
To Hear Kian Sadeghi tell it, his genetic testing company just might upend health care. The 23-year-old college dropout began working on Nucleus in 2020, from his bedroom in his parents’ Brooklyn home. From a swab of genetic material, he says, his company can glean insights into which drugs a person should be prescribed, which diet will best help them lose weight, and how concerned they should be about getting Alzheimer’s, among many other health considerations.
Sadeghi has received millions of dollars in financial backing from some of the most influential figures in Silicon Valley, including venture capital firms led by Reddit co-founder Alexis Ohanian and billionaire Peter Thiel. “It’s an inevitability that every single person has their entire human genome on their iPhone,” Sadeghi told Ohanian in a promotional video released on X, the platform formerly known as Twitter, in July 2022. “Who’s going to analyze it? Who’s going to store it? Who’s going to maintain it?” he said. “It’s going to be Nucleus.”
Sadeghi, who studied computational biology during his year-and-a-half as an undergraduate, asserts that he can...
Related Articles
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...
By Staff, ScienceDaily | 01.05.2026
Scientists at UNSW Sydney have developed a new form of CRISPR technology that could make gene therapy safer while also resolving a decades-long debate about how genes are switched off. The research shows that small chemical markers attached to DNA
...
Following a long-standing CGS tradition, we present a selection of our favorite Biopolitical Times posts of the past year.
In 2025, we published up to four posts every month, written by 12 authors (staff, consultants and allies), some in collaboration and one simply credited to CGS.
These titles are presented in chronological order, except for three In Memoriam notices, which follow. Many more posts that are worth your time can be found in the archive. Scroll down and “VIEW...
By Jonathan Matthews, GMWatch | 12.11.2025
In our first article in this series, we investigated the dark PR tactics that have accompanied Colossal Bioscience’s de-extinction disinformation campaign, in which transgenic cloned grey wolves have been showcased to the world as resurrected dire wolves – a...